PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
Public ClinicalTrials.gov record NCT01566773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control
Study identification
- NCT ID
- NCT01566773
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- PT001 MDI Drug
- Tiotropium Bromide Drug
- PT001 Placebo MDI Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
- Last update posted
- Oct 11, 2017
2012
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pearl Investigative Site | Fullerton | California | 92835 | — |
| Pearl Investigative Site | Clearwater | Florida | 33765 | — |
| Pearl Investigative Site | Panama City | Florida | 32405 | — |
| Pearl Investigative Site | Tampa | Florida | 33603 | — |
| Pearl Investigative Site | Winter Park | Florida | 32789 | — |
| Pearl Investigative Site | Charlotte | North Carolina | 28207 | — |
| Pearl Investigative Site | Medford | Oregon | 97504 | — |
| Pearl Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Pearl Investigative Site | Longview | Texas | 75605 | — |
| Pearl Investigative Site | Richmond | Virginia | 23225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01566773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01566773 live on ClinicalTrials.gov.